Global Bunyavirus Infections Market, By Genus Type (Hantavirus, Nairovirus, Phlebovirus, Orthobunyavirus), Disease Type (California Encephalitis, Arboviral Encephalitis, Akabane Virus Infection, Rift Valley Fever Infections, Sandfly Fever, Hemorrhagic Fever, Hantavirus Pulmonary Syndrome (HPS), CCHFV Infections), Host (Mosquitoes, Plebotomine Flies, Ticks, Culicoid Flies, Rodents), Treatment (Antiviral Drugs, Antihypotensive Agent, Fluid Replacement, Supportive Therapy, Surgery, Others), Diagnosis (Blood Tests, Virus Isolation, Polymerase Chain Reaction (PCR), Serologic Testing, Others), Symptoms (Plasma Viremia, Neuronal Necrosis, Mild Febrile Illness, Hemorrhagic Manifestations, Kidney Failure, Pulmonary Edema , Severe Respiratory Disease, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
n
Market Analysis and Insights Global Bunyavirus Infections Market
Bunyavirus infections market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 4.90% in the above mentioned forecast period.
Bunyavirus infection is a type of viral disease which occurs due to Bunyaviruses. Bunyaviruses belongs to the family Bunyaviridae. The viruses are spherical in shape and consist three segments of antisense single-stranded RNA combined with nucleoprotein. They contain enveloped virions which are approximately 80-120nm in diameter. Five genera including Phlebovirus, Orthobunyavirus, Tospovirus, Nairovirus, and Hantavirus are involved in the bunyavirus family. Mosquitoes, plebotomine flies, ticks, culicoid flies, and rodents are the major host transmitting this virus. Signs and symptoms of this infection includes plasma viremia, neuronal necrosis, mild febrile illness, hemorrhagic manifestations, kidney failure, pulmonary edema, severe respiratory disease and others.
The rise in the prevalence of bunyavirus infections will act as major driver that will results in the expansion of market’s growth. Another significant factor influencing the growth rate of bunyavirus infections market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, rising initiatives by public and private organisations to spread awareness and growing government funding are the factors that will expand the bunyavirus infections market. Other factors such as increase in the demand for effective therapies and rising geriatric population will positively impact the bunyavirus infections market’s growth rate. Additionally, upsurge in the number of clinical trials studies and growing use of insecticides and repellents will result in the expansion of bunyavirus infections market.
Moreover, the rise in the research and development activities and launch of effective therapies will provide beneficial opportunities for the bunyavirus infections market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate bunyavirus infections market in future.
However, high cost associated with the supportive treatment and lack of infrastructure in low-income countries will impede the growth rate of bunyavirus infections market. Additionally, side effects involved with the ribavirin such as rash, hives, difficulty breathing, depression, weight loss, heartburn, swelling, confusion, vision changes and hoarseness, among others will hinder the bunyavirus infections market growth. Less awareness about preventive methods will further challenge the market in the forecast period mentioned above.
This bunyavirus infections market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Bunyavirus infections market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Bunyavirus Infections Market Scope and Market Size
The bunyavirus infections market is segmented on the basis of genus type, disease type, host, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of genus type, the bunyavirus infections market is segmented into Hantavirus, Nairovirus, Phlebovirus, and Orthobunyavirus.
- On the basis of disease type, the bunyavirus infections market is segmented into California encephalitis, arboviral encephalitis, akabane virus infection, Rift valley fever infections, sandfly fever, hemorrhagic fever, Hantavirus pulmonary syndrome (HPS), and CCHFV infections.
- On the basis of host, the bunyavirus infections market is segmented into mosquitoes, plebotomine flies, ticks, culicoid flies, and rodents.
- On the basis of treatment, the bunyavirus infections market is segmented into antiviral drugs, antihypotensive agent, fluid replacement, supportive therapy, surgery and others. Antiviral drugs segment is further sub-segmented into ribavirin and others.
- On the basis of diagnosis, the bunyavirus infections market is segmented into blood tests, virus isolation, polymerase chain reaction (PCR), serologic testing and others.
- On the basis of symptoms, the bunyavirus infections market is segmented into plasma viremia, neuronal necrosis, mild febrile illness, hemorrhagic manifestations, kidney failure, pulmonary edema, severe respiratory disease and others.
- On the basis of dosage, the bunyavirus infections market is segmented into injection, tablets, and others.
- On the basis of route of administration, the bunyavirus infections market is segmented into oral, intravenous and others.
- On the basis of end-users, the bunyavirus infections market is segmented into clinic, hospital and others.
The bunyavirus infections market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Bunyavirus Infections Market Country Level Analysis
The bunyavirus infections market is segmented on the basis of genus type, disease type, host, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel.
The countries covered in the bunyavirus infections market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the bunyavirus infections market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Bunyavirus infections market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Bunyavirus Infections Market Share Analysis
Bunyavirus infections market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to bunyavirus infections market research.
Some of the major players operating in the bunyavirus infections market are Aurobindo Pharma, Siegfried Holding AG, STAR LAKE BIOSCIENCE, Curia Global, Inc., Zhejiang Chengyi Pharmaceutical Co., Ltd., Shaoxing Hantai Pharmaceutical Co., Ltd., Aprazer, Lancer Therapeuticals, Wellona Pharma Private Limited., SPARK LIFESCIENCES, Cipla Inc., Pfizer Inc., Mylan N.V., Norvartis AG, Endo Pharmaceuticals plc, Fresenius Kabi AG, Akorn Incorporated, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceutical Inc., and Bausch Health Companies Inc., among others.
SKU-